Trial Profile
Phase 2 Study of Denosumab in Combination With a PD-1 Inhibitor in Subjects With Stage III/IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Planned primary completion date changed from 15 Nov 2022 to 15 Apr 2023.
- 20 Jul 2022 Status changed from recruiting to active, no longer recruiting.